Peninsula Capital, an independent investment firm, completed the acquisition of a 20% stake in Galenicum, a global pharmaceutical company. Financial terms were not disclosed. Peninsula Capital's investment comes at a time of growth for Galenicum. This will close 2021 with a turnover of around €140m, and in the last five years it has experienced sales growth of 15% per year. Some increases that are explained, above all, by the launch of drugs developed by the company itself, in collaboration with large pharmaceutical groups.